Impact News +++ Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded... (GlobeNewswire EN) +++ WAVE LIFE SCIENCES Aktie -3,03%

HERON THERAPEUTICS Aktie

>Aktienkurs

1.165 EUR (Tradegate)

Ask: 1.186 EUR / 1400 Stück

Bid: 1.143 EUR / 1450 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>Performance

1 Woche: +17,4%

1 Monat: +23,9%

3 Monate: +2,0%

6 Monate: -35,0%

1 Jahr: -31,0%

laufendes Jahr: -19,4%

>HERON THERAPEUTICS Aktie

Name:

HERON THERAPEUTICS DL-,01

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US4277461020 / A1XB6K

Symbol/ Ticker:

AXD2 (Frankfurt) / HRTX (NASDAQ)

Kürzel:

FRA:AXD2, ETR:AXD2, AXD2:GR, NASDAQ:HRTX

Index:

Webseite:

https://www.herontx.com/

Profil:

Heron Therapeutics Inc. is a biotechnology company..
>Volltext..

Marktkapitalisierung:

206.33 Mio. EUR

Unternehmenswert:

285.44 Mio. EUR

Umsatz:

133.23 Mio. EUR

EBITDA:

3.83 Mio. EUR

Nettogewinn:

-11.66 Mio. EUR

Gewinn je Aktie:

-0.07 EUR

Schulden:

120.64 Mio. EUR

Liquide Mittel:

36.99 Mio. EUR

Operativer Cashflow:

-25.93 Mio. EUR

Bargeldquote:

0.62

Umsatzwachstum:

6.84%

Gewinnwachstum:

53.93%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

HERON THERAPEUTICS, HERON THERAPEUTIC

Letzte Datenerhebung:

08.12.25

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 183.36 Mio. St.

Frei handelbar: 99.06%

Leerverk. Aktien: 19.96%

Rückkaufquote: -12.04%

Mitarbeiter: 122

Umsatz/Mitarb.: 1.02 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 303.22%

Bewertung:

KGV: -

KGV lG: -

KUV: 1.29

KBV: 29.77

PEG-Ratio: -

EV/EBITDA: 74.59

Rentabilität:

Bruttomarge: 73.92%

Gewinnmarge: -8.75%

Operative Marge: 1.35%

Managementeffizenz:

Gesamtkaprendite: -5.78%

Eigenkaprendite: -

>Peer Group

Es sind 599 Aktien bekannt.

>Chart & Kurs - NASDAQ

>Alle News

04.12.25 - 14:18

Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV) (GlobeNewswire EN)

CARY, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced the inclusion of APONVIE® (aprepitant) injectable emulsion in the newly released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting: Executive Summary and Full Report as published in Anesthesia and Analgesia (collectively, the “PONV Guidelines”)....

04.11.25 - 21:33	Heron Therapeutics outlines $153M–$163M net revenue target as acute care momentum accelerates (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

04.11.25 - 16:45	Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
	Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers....

04.11.25 - 15:54	Q3-Zahlen von Heron Therapeutics: Umsatz und Gewinn enttäuschen Anleger (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

04.11.25 - 14:09	Heron Therapeutics GAAP EPS of -$0.10 misses by $0.09, revenue of $38.2M misses by $0.83M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

03.11.25 - 17:27	Heron Therapeutics Q3 2025 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

29.10.25 - 23:00

Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors (GlobeNewswire EN)

CARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced the appointment of Thomas Cusack to its Board of Directors. Mr. Cusack has extensive experience in matters related to corporate finance, investment management, and corporate governance. Mr. Cusack was appointed to the Board pursuant to the Cooperation Agreement entered into between the Company and Rubric Capital Management LP, dated as of August 8, 2025....

21.10.25 - 22:21	Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 (GlobeNewswire EN)
	Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025...

09.09.25 - 23:33	Heron Therapeutics files $125M mixed securities shelf (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

15.08.25 - 13:48	Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value (PR Newswire)
	CARY, N.C., Aug. 15, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that its Board of Directors (the "Board") has adopted a Section 382 rights plan (the "Rights Plan") designed to protect......

13.08.25 - 04:02	Insiderhandel: Insider kauft Aktien von Heron Therapeuti im Wert von 3580838 USD (Insiderkauf)
	Rubric Capital Management Lp - Zehn-Prozent-Eigentümer - Tag der Transaktion: 2025-08-08...

13.08.25 - 00:01	Insiderhandel: Aufsichtsrat kauft Aktien von Heron Therapeuti im Wert von 2649819 USD (Insiderkauf)
	Morgan, Adam - Aufsichtsrat - Tag der Transaktion: 2025-08-08...

08.08.25 - 21:48	Heron Therapeutics raises adjusted EBITDA guidance to $9M-$13M for 2025 amid commercial restructuring and ZYNRELEF J-code milestone (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

08.08.25 - 16:45	Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
	Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers....

08.08.25 - 14:45	Heron Therapeutics announces capital restructuring to support growth (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

08.08.25 - 13:54	Heron Therapeutics GAAP EPS of -$0.02 misses by $0.01, revenue of $37.2M misses by $0.88M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

08.08.25 - 13:48	Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress (PR Newswire)
	Generated Q2 2025 Net Revenue of $37.2 million and year-to-date revenue of $76.1 million; reaffirmed 2025 Net Revenue Guidance of $153 million - $163 million Delivered record year-to-date 2025 Adjusted EBITDA of $7.9 million, raised full-year 2025 Adjusted EBITDA Guidance from $4.0......

08.08.25 - 13:48	Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile (PR Newswire)
	CARY, N.C., Aug. 8, 2025 Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the completion of a comprehensive capital restructuring designed to enhance the Company's financial flexibility, reduce total debt, and......

08.08.25 - 12:03	Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025 (PR Newswire)
	CARY, N.C., Aug. 8, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that it has rescheduled its release of second quarter 2025 financial results and subsequent conference call. The Company......

29.07.25 - 03:45	Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025 (PR Newswire)
	CARY, N.C., July 28, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, August 11, 2025, at 4:30 p.m. ET to report......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Ist das Maisfeld fern vom Haus, fressen die Vögel die Frucht. - Sprichwort Pygmäen

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram